Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 15/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556325 | 0.84 | RXFP1 (0.50) | RXFP1ABCG2PTGS1SMN1; SMN2MAPK8 | |
| SCHEMBL22556312 | 0.84 | RXFP1 (0.50) | RXFP1ABCG2PTGS1SMN1; SMN2MAPK8 | |
| SCHEMBL22556346 | 0.82 | RXFP1 (0.48) | RXFP1ABCG2PTGS1SMN1; SMN2MAPK8 | |
| SCHEMBL22571423 | 0.81 | RXFP1 (0.47) | RXFP1ABCG2PTGS1SMN1; SMN2MAPK8 | |
| SCHEMBL23713160 | 0.80 | RXFP1 (0.47) | RXFP1ABCG2PTGS1SMN1; SMN2MAPK8 | |
| SCHEMBL23713153 | 0.78 | RXFP1 (0.49) | RXFP1ABCG2PTGS1SMN1; SMN2MAPK8 | |
| SCHEMBL22556334 | 0.78 | RXFP1 (0.53) | RXFP1ABCG2SMN1; SMN2MAPK8NPC1 | |
| SCHEMBL22556306 | 0.77 | RXFP1 (0.53) | RXFP1ABCG2PTGS1SMN1; SMN2MAPK8 | |
| SCHEMBL23701544 | 0.76 | RXFP1 (0.47) | RXFP1ABCG2MAPK8NPC1RAB9A | |
| SCHEMBL22556300 | 0.76 | RXFP1 (0.49) | RXFP1ABCG2PTGS1SMN1; SMN2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3793551-A1 | OXADIAZOLE COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885ABCG2 2985/4885PTGS1 2113/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885ABCG2 2985/4885PTGS1 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.